Tính kháng thuốc của M. Tuberculosis ở người bệnh có xpert MTB/RIF kháng rifampicin được điều trị phác đồ ngắn hạn=Drug resistance of M. Tuberculosis in patients with rifampicin-resistant xpert MTB/RIF treated with a short-term regimen

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Gregory Fox, Bình Hòa Nguyễn, Thị Liên Hà Nguyễn, Thu Anh Nguyễn, Quốc Đạt Vũ

Ngôn ngữ: vie

Ký hiệu phân loại:

Thông tin xuất bản: Tạp chí Nghiên cứu y học (Đại học Y Hà Nội), 2024

Mô tả vật lý: tr.46-55

Bộ sưu tập: Metadata

ID: 244700

Thêm vào giỏ

Over the past two decades, the emergence of multidrug-resistant tuberculosis has significantly complicated global efforts to control the tuberculosis epidemic. This study aims to describe the antibiotic resistance profiles of Mycobacterium tuberculosis in Vietnamese patients with Rifampicin resistance by Xpert MTB/RIF. We conducted a descriptive, retrospective study on 752 tuberculosis patients with Rifampicin resistance by Xpert MTB/RIF who received a short-course treatment at 35 medical facilities as part of the Resistant TB Management Program in 7 provinces in Vietnam. Among them, 118 cases with isolated M. tuberculosis strains and had antibiotic resistance profiles, the rate of M. tuberculosis resistant to each drug of second-line anti-tuberculosis antibiotic is Moxifloxacin (6.96%)
Amikacin (3.39%)
Ofloxacin/Levofloxacin (3.51%)
Kanamycin (3.39%)
Capreomycin (3.39%). Ethionamide, Bedaquiline, and Delamanid were not resistant. Given the high rate of drugresistant M. tuberculosis and the high burden of tuberculosis in Vietnam, it is important to collect the susceptibility data for key second line drugs to monitor the drug resistance trend and individualize the treatment regimen for those who have resistance to first-line anti-tuberculosis.Sự xuất hiện của bệnh lao đa kháng thuốc làm phức tạp đáng kể những nỗ lực nhằm kiểm soát dịch bệnh lao toàn cầu. Mục tiêu nghiên cứu nhằm mô tả đặc điểm kháng kháng sinh của Mycobacterium tuberculosis ở người bệnh có kết quả Xpert MTB/RIF kháng Rifampicin tại Việt Nam. Nghiên cứu mô tả, hồi cứu trên 752 người bệnh lao có kết quả Xpert MTB/RIF kháng với Rifampicin, nhận điều trị phác đồ ngắn hạn tại 35 cơ sở y tế trong Chương trình Quản lý Lao kháng thuốc ở 7 tỉnh tại Việt Nam. Trong số đó, có 118 trường hợp phân lập được M. tuberculosis và làm kháng sinh đồ. Tỷ lệ M. tuberculosis kháng từng loại kháng sinh chống lao hàng 2 là Moxifloxacin (6,96%)
Amikacin (3,39%)
Ofloxacin/Levofloxacin (3,51%)
Kanamycin (3,39%)
Capreomycin (3,39%). Có 3 thuốc chưa xuất hiện tình trạng đề kháng là Ethionamide, Bedaquiline và Delamanid. Nghiên cứu chỉ ra sự cần thiết phải theo dõi tính nhạy cảm với các thuốc chống lao hàng hai và cá thể hóa phác đồ điều trị cho những người kháng thuốc chống lao hàng một.

1. Đọc trực tuyến

1. Đọc trực tuyến

Tạo bộ sưu tập với mã QR